Brainsway Ltd ADR (BWAY) Stock Price, Quote & News

Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitatio...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 2 582 4030

Website: www.brainsway.com

Address:

16 Hartum St, Har Hotzvim, Jerusalem, Israel

prismmarketview Nov. 13 at 9:37 PM

(NASDAQ: $BWAY) #BrainsWay's Deep TMS™ system has received FDA clearance for use as an adjunct therapy in adolescents aged 15 to 21 with major depressive disorder. This makes it the first TMS device cleared to treat depression across the widest age range, from 15 to 86 years. The approval is based on real-world data showing meaningful improvement in depression symptoms with a good safety profile. Deep TMS offers a noninvasive treatment option alongside other therapies for adolescents with depression. https://prismmarketview.com/brainsway-gains-fda-clearance-for-deep-tms-as-adjunct-therapy-for-adolescents-with-major-depressive-disorder/

0 · Reply

JarvisFlow Nov. 13 at 6:01 PM

HC Wainwright & Co. has updated their rating for BrainsWay ( $BWAY ) to Buy with a price target of 18.

0 · Reply

OpenOutcrier Nov. 13 at 1:12 PM

$BWAY (+4.5% pre) BrainsWay (NASDAQ: BWAY) wins FDA 510(k) to add Deep TMS adjunct for MDD in ages 15–21 https://ooc.bz/l/84353

0 · Reply

BrainsWay Nov. 13 at 11:19 AM

$BWAY BrainsWay continues to expand its leadership in mental health innovation, exploring new therapeutic indications, faster treatment protocols, and broader market adoption through strategic collaborations such as our recent investment in NeuroLief. Here is what our CEO, Hadar Levy, had to say in the recent Q3 earnings press release. #BrainsWay #BrainsWayLTD #TMS #DeepTMS #BrainHealth

0 · Reply

JarvisFlow Nov. 12 at 6:07 PM

Northland Capital Markets has adjusted their stance on BrainsWay ( $BWAY ), setting the rating to Outperform with a target price of 19 → 23.

0 · Reply

BrainsWay Nov. 12 at 2:41 PM

$BWAY Q3 of 2025 has been a record-breaking quarter for BrainsWay. In yesterday’s announcement, we proudly shared our recent financial and operational highlights. In case you missed it, read our official earnings release here: https://finance.yahoo.com/news/brainsway-reports-third-quarter-2025-123000184.html You can also rewatch our live earnings announcement conference call from yesterday, here: https://viavid.webcasts.com/starthere.jsp?ei=1739288&tp_key=977db37f6c

0 · Reply

FordFG Nov. 11 at 3:47 PM

$BWAY so why is this down 9% after a great earnings report??

0 · Reply

BrainsWay Nov. 11 at 3:13 PM

$BWAY We at BrainsWay are thrilled to announce our record-breaking Q3 2025 Financial Results and Operational Highlights. Revenue has surged 29% to $13.5 million in Q3 2025 compared to Q3 2024, an incredible increase that underscores the growing impact and success of TMS at BrainsWay. Further highlights include: • Operating income reached $1.3 million, and Adjusted EBITDA climbed ~80% to $2.0 million • Remaining performance obligations grew to $65 million, reflecting strong multi-year customer demand • The FDA cleared an accelerated Deep TMS™ protocol for patients with major depressive disorder (MDD) • Raised midpoint of full-year 2025 Revenue and EBITDA guidance Read the full press release here: https://www.globenewswire.com/news-release/2025/11/11/3185329/17676/en/BrainsWay-Reports-Third-Quarter-2025-Financial-Results-and-Operational-Highlights.html

0 · Reply

OpenOutcrier Nov. 11 at 1:24 PM

$BWAY (+3.0% pre) BrainsWay GAAP EPS of $0.04 in-line, revenue of $13.51M beats by $0.47M https://ooc.bz/l/84040

0 · Reply

DARKP00L Nov. 4 at 1:34 PM

$BWAY 08:09 on Nov. 04 2025 BrainsWay Awarded $2.5M Grant From U.S. NIH To Support Clinical Trial Evaluating Deep Transcranial Magnetic Stimulation Protocol Through BrainsWay's Device For Alcohol Use Disorder Treatment #tradeideas

0 · Reply

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Nov 11, 2025, 10:41 AM EST - 3 days ago

BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:30 AM EST - 3 days ago

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 4, 2025, 8:00 AM EST - 10 days ago

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

Oct 28, 2025, 8:00 AM EDT - 17 days ago

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

Oct 27, 2025, 7:30 AM EDT - 18 days ago

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Aug 21, 2025, 7:30 AM EDT - 3 months ago

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

Aug 20, 2025, 7:30 AM EDT - 3 months ago

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Aug 13, 2025, 3:21 PM EDT - 3 months ago

BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 3 months ago

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Jun 11, 2025, 7:30 AM EDT - 5 months ago

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Jun 10, 2025, 8:00 AM EDT - 5 months ago

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

Jun 4, 2025, 7:30 AM EDT - 5 months ago

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

May 13, 2025, 10:16 AM EDT - 6 months ago

BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 6 months ago

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

Mar 11, 2025, 10:17 AM EDT - 8 months ago

BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 8 months ago

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dec 12, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

Nov 20, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Nov 12, 2024, 12:59 PM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Oct 29, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

Oct 9, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

Sep 30, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Sep 16, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces Significant Expansion on U.S. East Coast

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

Aug 29, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Appoints Richard A. Bermudes, M.D.

Aug 13, 2024, 4:40 AM EDT - 1 year ago

BrainsWay: Operating Leverage Driving Upside

Aug 6, 2024, 12:03 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 23, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 17, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

Jun 10, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Jun 3, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression

May 9, 2024, 9:00 AM EDT - 1 year ago

BrainsWay: Cash Flows Are Underappreciated

May 8, 2024, 1:16 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 24, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Mar 18, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Mar 6, 2024, 10:04 AM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Feb 21, 2024, 8:00 AM EST - 1 year ago

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Jan 10, 2024, 7:30 AM EST - 2 years ago

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

Dec 19, 2023, 7:30 AM EST - 2 years ago

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Dec 7, 2023, 8:00 AM EST - 2 years ago

BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

Nov 20, 2023, 7:30 AM EST - 2 years ago

Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives

Nov 20, 2023, 12:01 AM EST - 2 years ago

BrainsWay: Positive Cash Flow And Continued Growth

Nov 15, 2023, 2:52 PM EST - 2 years ago

Brainsway Ltd (BWAY) Q3 2023 Earnings Call Transcript

Nov 15, 2023, 7:30 AM EST - 2 years ago

BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights

prismmarketview Nov. 13 at 9:37 PM

0 · Reply

JarvisFlow Nov. 13 at 6:01 PM

HC Wainwright & Co. has updated their rating for BrainsWay ( $BWAY ) to Buy with a price target of 18.

0 · Reply

OpenOutcrier Nov. 13 at 1:12 PM

$BWAY (+4.5% pre) BrainsWay (NASDAQ: BWAY) wins FDA 510(k) to add Deep TMS adjunct for MDD in ages 15–21 https://ooc.bz/l/84353

0 · Reply

BrainsWay Nov. 13 at 11:19 AM

0 · Reply

JarvisFlow Nov. 12 at 6:07 PM

Northland Capital Markets has adjusted their stance on BrainsWay ( $BWAY ), setting the rating to Outperform with a target price of 19 → 23.

0 · Reply

BrainsWay Nov. 12 at 2:41 PM

0 · Reply

FordFG Nov. 11 at 3:47 PM

$BWAY so why is this down 9% after a great earnings report??

0 · Reply

BrainsWay Nov. 11 at 3:13 PM

0 · Reply

OpenOutcrier Nov. 11 at 1:24 PM

$BWAY (+3.0% pre) BrainsWay GAAP EPS of $0.04 in-line, revenue of $13.51M beats by $0.47M https://ooc.bz/l/84040

0 · Reply

DARKP00L Nov. 4 at 1:34 PM

0 · Reply

BrainsWay Oct. 30 at 8:32 AM

$BWAY BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025 Ahead of the call, here’s a look back at Q2 2025 highlights: BrainsWay closed a record-breaking quarter (Q2), reflecting strong demand for our noninvasive neurostimulation tech & commitment to advancing mental health care. Key Highlights: • Revenue: $12.6M, up 26% YoY • EBITDA: +40% YoY in H1 2025 • Net Profit: $2M, up 240% YoY • Performance Obligations: $62M, up 25% YoY • Cash Flow: 8 consecutive quarters of positive free cash flow • Guidance: Raised full-year 2025 Revenue and EBITDA outlook Operational Momentum: • 88 systems shipped in Q2 (+35% YoY); global installed base reached 1,522 systems • ~70% of recent customer engagements structured as multi-year lease agreements Strategic Partnerships: • Completed equity financings with Stella MSO and Axis MSO, two leading clinic networks

0 · Reply

BrainsWay Oct. 28 at 12:37 PM

$BWAY BrainsWay Expands in Europe 🌍 BrainsWay is pleased to announce Axontronic as our new exclusive distributor for the DACH region, covering Germany, Switzerland, and Austria. Following a comprehensive evaluation process, we’re confident that our new partner will uphold BrainsWay’s best practice standards and help expand access to our Deep TMS™ technology across these key markets. A warm welcome to CEO and founder Richard Brandmeier and the entire Axontronic team as they join the BrainsWay partner family. #BrainsWay $BWAY #DeepTMS #MentalHealth #NeuroTech

0 · Reply

BrainsWayResponder Oct. 28 at 12:23 PM

$BWAY | Official Responder Launch 🚀 Welcome to the official BrainsWay Responder account! This profile is managed in coordination with the BrainsWay team to ensure accurate, timely, and transparent communication with our shareholders. Through this channel, we’ll: • Answer shareholder questions with factual responses. • Clarify public information and company updates. • Address misinformation circulating online. • Help investors better understand our progress and vision. Our mission is to make engagement between BrainsWay and the investment community more open, informed, and accessible. 💬 Have a question about $BWAY or our ongoing programs? Ask us here, our team is listening and ready to respond.

0 · Reply

BEATOFtheMARKET Oct. 24 at 10:52 PM

$BWAY $BVN $BUSE $BULU $BUD 🔥

0 · Reply

BrainsWay Oct. 21 at 11:06 AM

$BWAY BrainsWay’s recent FDA clearance for its accelerated Deep TMS protocol isn’t just a milestone; it’s a turning point. By reducing treatment time from 4 weeks to just 6 days, this breakthrough could reshape how depression is treated and open the door to wider clinical adoption. As clinics, patients, and insurers begin to recognize the impact of this faster, more accessible approach, the commercial potential for Deep TMS continues to grow. #BrainsWay #DeepTMS #FDAApproval #MentalHealth #InvestorNews #Neurotech

0 · Reply

NickBFinanc Oct. 20 at 9:01 PM

Are there other mental health or neurological indications $BWAY is currently studying for Deep TMS?

1 · Reply

BrainsWay Oct. 20 at 9:17 AM

$BWAY Deep TMS Is Redefining Mental Health Treatment Psychiatrist Dr. Muhamad Aly Rifai shares how BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) is delivering real results for patients battling severe depression, OCD, and other treatment-resistant conditions, sometimes in as little as five days. With remission rates up to 79% and a non-invasive, drug-free approach, Deep TMS is rapidly gaining traction as a next-generation solution in the $20B+ global mental health treatment market. As more clinics and providers adopt this technology, BrainsWay stands at the forefront of a major shift in psychiatric care. 🎥 Watch the full interview: youtube.com/watch?v=lJlXpt220ao

0 · Reply

ShelliRew Oct. 17 at 9:03 PM

$BWAY Here is the start to many more good news to come https://www.msn.com/en-us/money/topstocks/brainsway-ltd-announces-successful-outcomes-of-annual-shareholder-meeting/ar-AA1MnCMB?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

1 · Reply

daytrader_dav Oct. 15 at 2:33 PM

$BWAY what was it, $78M in cash? Above 70% in recurring revenues and a 90% retention rate. more should be on this. wild what $BWAY is doing with their technology and sales.

4 · Reply

NickBFinanc Oct. 8 at 6:11 PM

$BWAY I’ve been watching $BWAY for a bit now… the tech they’ve got in mental health is actually underrated. FDA cleared devices treating depression + OCD. Once the market wakes up to how scalable this is, this will jump. If BrainsWay gets more insurance coverage + awareness, this could move way higher from $15.

1 · Reply

BrainsWay Oct. 8 at 4:45 PM

$BWAY Featured in MassDevice: BrainsWay has received expanded FDA clearance for our Deep TMS™ system, now including an accelerated treatment protocol for Major Depressive Disorder (MDD) and patients with comorbid anxiety symptoms. 🔹 6 treatment days vs. 4 weeks under the standard protocol 🔹 Each session lasts less than 10 minutes 🔹 Supported by a multicenter, randomized, controlled study 🔹 Comparable efficacy with fewer clinic visits Read the full MassDevice feature: https://lnkd.in/eHMBefcf

0 · Reply

BrainsWay Oct. 6 at 4:29 PM

$BWAY The global mental health app market is projected to reach $17.5 billion by 2030. At BrainsWay, we believe treatment must be fast, data-driven, and deeply human. Our mission is to equip clinics, providers, and patients with the next generation of solutions. In our latest milestone, we’ve received FDA clearance for the Accelerated Deep TMS Protocol, a breakthrough in non-invasive treatment for Major Depressive Disorder (MDD). And with 4 FDA-cleared indications, MDD, OCD, Anxious Depression, and Smoking Addiction, we are advancing on critical fronts to ensure care evolves with both urgency and technology. 🚀 Our Innovation Pipeline: - Insights Cloud - Data-driven clinical intelligence - TMS 360 - A complete platform for interventional care - AI Personalization - Protocols tailored to every brain - Complementary Home Device - Extending treatment beyond the clinic

0 · Reply

Market Cap	304.25M
Revenue (ttm)	41.02M
Net Income (ttm)	2.92M
EPS (ttm)	N/A
PE Ratio	52.60
Forward PE	44.66
Profit Margin	7.12%
Debt to Equity Ratio	0.00

Volume	46,600
Avg Vol	67,172
Day's Range	N/A - N/A
Shares Out	19.00M
Stochastic %K	43%
Beta	1.22
Analysts	Strong Sell
Price Target	$19.53